Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.04% | 48.15% | 66.29% | 61.20% | 4.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.08% | 28.79% | 33.21% | 23.16% | -13.88% |
| Operating Income | -23.08% | -28.79% | -33.21% | -23.16% | 13.88% |
| Income Before Tax | -24.60% | -15.00% | -28.61% | -27.99% | 3.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.60% | -15.00% | -28.61% | -27.99% | 3.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.60% | -15.00% | -28.61% | -27.99% | 3.52% |
| EBIT | -23.08% | -28.79% | -33.21% | -23.16% | 13.88% |
| EBITDA | -23.59% | -29.18% | -33.45% | -23.39% | 13.99% |
| EPS Basic | -7.15% | -1.05% | -16.80% | -20.72% | 7.73% |
| Normalized Basic EPS | -7.17% | -1.07% | -16.89% | -20.81% | 7.74% |
| EPS Diluted | -7.15% | -1.05% | -16.80% | -20.72% | 7.73% |
| Normalized Diluted EPS | -7.17% | -1.07% | -16.89% | -20.81% | 7.74% |
| Average Basic Shares Outstanding | 18.76% | 15.55% | 11.02% | 5.65% | 4.44% |
| Average Diluted Shares Outstanding | 18.76% | 15.55% | 11.02% | 5.65% | 4.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |